When disposition is monoexponential, extravaseular concentration-time (C, t) data yield both disposition and absorption parameters, the latter via the
INTRODUCTION
Compartment analysis has been and still is the most common approach to pharmacokinetic characterization of a drug in the body (1) (2) (3) . Usually such a system of compartments has no anatomic or physiological reality. For those compartments involved in disposition of the drug the rates of transfer between compartments is assumed to obey first-order kinetics if the system is linear. It is not necessary to assume first-order kinetics for transfer of drug from an extravascular absorption site to the systemic circulation.
The purposes of pharmacokinetics are (i) to reduce data to meaningful numbers or parameters, (ii) to use the reduced data to make predictions of results of future experiments or predictions of results of a host of studies that would be too costly and time-consuming to be carried out (2) , (iii) to allow quantitative correlation with pharmacodynamic effects, and (iv) to provide pharmaceutical scientists with quantitative methods to determine the effects of formulation factors on performance of dosage forms of drugs in animals and human beings.
To perform item (iv) above one usually requires absorption plots, and, classically, these have been obtained by methods outlined below. When disposition is monoexponential one estimates the first-order elimination rate constant from postabsorptive concentration-time data and then applies the Wagner-Nelson method (4) to data in the absorptive phase to obtain values of A-r~ V (amount of drug absorbed to time T divided by the volume of distribution) as a function of time. Frequently, but not always, these values can be fitted to one of the absorption functions listed below in order to estimate one or more absorption rate constants. As a result of intrasubject variation of the elimination rate constant (~.~) of many drugs it is our opinion that this disposition parameter should not be estimated from data derived from a different treatment than the data being analyzed for absorption.
Classically, when disposition is bi-or triexponential the drug has been administered intravenously first, then extravascularly second. There have been two approaches: (i) Compartment model disposition parameters have been derived from the intravenous data, then these used in application of either the Loo-Riegelman method (5) or the Exact Loo-Riegelman method (6) , as modified by Proost (7) , to obtain values of AT/Vp (amount of drug absorbed to time T divided by the volume of the central compartment) as a function of time; or, (ii) deconvolution is applied (8-11) using both the intravenous and extravascular data. Again, the AT/Vp vs. time data may frequently be fitted to an absorption function similar to one of those listed below and one or more absorption rate constants estimated.
The methods described above, which use intravenous data to evaluate extravascular data, involve the assumption that there is constancy of disposition parameters of the drug. This constitutes an hypothesis and there is evidence with many drugs that this hypothesis has to be rejected (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . Some authors (14, 16) have reported areas under concentration-time curves (A UC), while others have reported elimination half-lives (12, 14, 17) following administration of multiple single doses and have calculated measures of intra-and intersubject variation. We believe that clearances, rather than A UCs, and elimination rate constants, rather than half-lives, should be analyzed for intra-and intersubject variation. We have reevaluated those data and have added evaluations of similar data (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) using the method outlined in Table I , where the intrasubject coefficient of variation (CV) has been estimated for each subject from the four oral clearances measured on Days 2, 8, 16 , and 21 ; the lowest, highest, and median CVs are then obtained and are reported in Table II . The grand mean parameter value and the intersubject CV is estimated from the subject means as indicated in Table I and these are also shown in Table II . The intrasubject variation in the pharmacokinetic parameters listed in Table II may be the result of intrasubject variation in distribution and/or elimination. The data in Table II Table II Table II the median intrasubject CV is greater than the intersubject CV.
Here we develop several methods to estimate disposition parameters of the classical two-and three-compartment disposition models from postabsorptive extravascular (oral, im, subcutaneous, etc.) data without the need for intravenous data.
The purposes of this article are (i) to describe the new methods to estimate classical two-and three-compartment disposition parameters from postabsorptive plasma (serum or whole blood) concentration-time data; (ii) to illustrate application of these methods to extravascular data of flurbiprofen, mesoridazine, flunarizine, labetalol, and diazepam, and present results of these pharmacokinetic analysis; (iii) to illustrate application of the Exact Loo-Riegelman method (6) with the Proost modification (7) to concentration-time data in the absorptive phase of the same data sets and present results of fitting Av/lip or fraction absorbed values to obtain the kinetics of absorption; and (iv) to show how results from (ii) and (iii) may be combined to allow reconstruction of the original concentration-time data.
EXPERIMENTAL

Format
Method 1 is the classical one where intravenous data are fitted with a bi-or triexponential equation and disposition rate constants are estimated from the coefficients and exponents of such equations by methods previously described (2, 3) .
In the Equations section below, equations needed to apply Methods 2, 3, 4, and 5 are given. The two-compartment open model and biexponential disposition is considered first, followed by the three-compartment open model and triexponential disposition. A Source of Equations section follows and the origins of the equations in the Equations section are given. These sections are followed by a section giving details of Applications of the Equations to extravascular data of specific drugs.
Methods 3 and 5 involve direct computer fitting of postabsorptive concentration-time data. If one uses the microcomputer program MINSQ (30) and the SIMPLEX method is initially used then no initial estimates of the parameters are required. Nonlinear least squares should always be the final method used. Methods 2 and 4 are most suited for cases where there has been zero-order input over a time v and hence the mean input time, MIT, is known, namely r/2.
Equations
The classical two-compartment open model is shown in Scheme 1. 
k2~-(3) klo kl2=~l +~2-klO-k21 (4) where MRT= (A UMC/A UC) -MIT (see Glossary).
Method 3A
Postabsorptive concentration-time data are computer fitted to Eq. (5) using the AUC from Eq. (6) and ,~ and ~z from Eq. (1) as constants and km and ts as estimated parameters.
C-AUC [Al(Z2-klo) e-X~(t-t~ e -&(~-ts)]
The C-r of Eq. (6) is given by Eq. (7), where T is the last sampling time.
Method 3B Postabsorptive concentration-time data are computer fitted to Eq. (5) with ,~, ~2, k~o and ts as estimated parameters, again using A UC from Eqs. (6) and (7) as a constant.
Method 4
This method assumes that the dose is absorbed at a zero-order rate over time r; postabsorptive concentration-time data are treated like postinfusion data and r is the time shift required to do this.
Method 5
This method makes the same assumption as in Method 4. Postabsorptive concentration-time data are computer fitted to Eq. (9) with Z~, 2~2, and A UC as constants and km and r as estimated parameters. Note that Z1 and ~2 are obtained in the initial fitting to Eq. (1).
C-AUC(Z2-kl~ ~:-l) e-~"-~ AUC(kl~ ZO(e+ Z:-l)
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In Methods 3A, 3B, 4, and 5 once kl0 has been estimated then k2t and kj2 are obtained from Eqs. (3) and (4) or (klo(2 2 _ Z~3) + ~1~223 ) e -z~(t-,0
Method 3B
Postabsorptive concentration-time data are computer-fitted to Eq. (11) with A UC [from Eqs. (6) and (7)] as a constant and ,~1,22, 23, kl0, Z, and ts as estimated parameters.
Method 5
This method assumes that the dose is absorbed at zero-order rate over time r; postabsorptive concentration-time data are treated like postinfusion data and ris the time shift required to.do this. Postabsorptive concentrationtime data are computer-fitted to Eq. (12) with ,~1, 22, ,~3, and AUC as constants and kin, and Z= k2~ + k31 as estimated parameters. 
AUMC STtC" dt+eT" T+CT
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In Eq. (13) AUC is obtained with Eq. (6) and ~'r with Eq. (7). The integrals in Eq. (6) and in Eq. (13) were estimated with a combination of the linear and logarithmic rules using the criterion of Proost (7) to choose which rule to use at a specific place in the data set.
Methods 2 and 4 cannot be satisfactorily applied to the model of Scheme 2 after addition of extravascular input.
Source of Equations
Source of Eq. (2)
For the model of Scheme 1, Wagner (32) showed that Eq. (14) held.
Rearrangement of Eq. (14) yields Eq. (2). The extravascular A UMC/ A UC is the sum of two mean residence time functions as indicated by Eq. (15) .
A UMC/A UC = MRT+ MIT
Hence,
MRT= A UMC/A UC-MIT (16)
Source of Eq. (5)
For the model of Scheme 1 and bolus intravenous administration the concentration, C, in compartment 1 is given by Eq. (17) (2,3).
Substituting for Co in Eq. (17) 
Source of Eq. (11)
The concentration, C, in the central compartment of the model of Scheme 2 after bolus intravenous administration is given by Eq. (24) 
Source of Eq. (12)
The postinfusion equation where an infusion at the rate k0 is put into compartment 1 over r hours and time is measured from the start of the infusion is Eq. (25) .
Substituting for ko/Vp in Eq. (25) 
Absorption Kinetics
The Exact Loo-Riegelman method (6) with the Proost modifications (7) was applied to each set of extravascular data analyzed by Methods (27) A~/Vp kl0' (AUC) Ao~ AT/Vp = (A ~/ Vp) { 1 -e-ka(t --tO)} (28) { l (kl e-k2'-k2 e-k't)} (29) AT/Vp=(A~/Vp) 1 k,-k2
(kl e-k2r e -~t) (32) kl -k2
It should be noted for Eq. (30) that when t-to is equal to the time when the dose has been absorbed then ko (t-to)=A~; the same thing is true for Eq. (33) in which case FA = 1 also. In Eqs. (28) and (29), A~/Vp was usually equal to kio(A UC).
Equations (28) and (31) are for simple first-order absorption with a lag time, to; Eqs. (29) and (32) are for two consecutive first-order processes without a lag time, where, for example, kl could refer to dissolution and stomach emptying and k2 refer to absorption across the gastrointestinal barrier, or vice versa, in the case of oral administration. Eqs. (30) and (33) are for zero-order absorption; note that when AT/Vp is plotted vs. t -to the slope of the least squares line is ko/Vp and when FA is plotted against t-to the slope of least square line is ko/A~.
Reconstructions
In this article on system analysis Veng Pedersen (33) stated: "Unfortunately, it is sometimes difficult and even impossible to reconstruct the basic drug level response from the parameters presented in pharmacokinetic studies." In the course of this research we have determined absorption and disposition parameters from 50 sets of extravascular concentration-time data and have successfully made reconstructions using the parameters estimated by each of the methods. In each case such a reconstruction is a theoretical trend line drawn through a plot of the original concentrationtime data and based on the complete compartment model elaborated by the stepwise procedure and the parameters which were estimated. The compartment models which were elaborated and the equations used in the reconstructions are shown below.
Mesoridazine (20 Sets) and Flurbiprofen (12 Sets)
The compartment model elaborated is shown as Scheme 3 and the 
I(k2~
-Z,) e -z'('-'~ (k21-Z2) e -z2('-'~ C=kaCo .... (/!,2 --,,~,) (ka -~,,) (,'t,1 -,;L2) (ka -Z2) (k21 -ka) e-~~176 1(34)
Flunarizine (5Sets)
The compartment model elaborated is shown as Scheme 4 and the reconstruction equation as Eq. (35) which was used for data for four patients showing first-order absorption and as Eqs. (36) and (37) changed to a zero-order rate constant, ko.
During zero-order absorption
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The compartment model elaborated is shown as Scheme 6 and the reconstruction equation as Eq. (40).
Simulations
Three sets of concentration-time data were generated with the model of Scheme 3 and Eq. (34) . The parameter to was made equal to zero in all cases, The three sets of data were derived using kl0, k12, k21, and k~ values very similar to those values which estimated from real flurbiprofen plasma concentrations measured following oral administration of a solution of the sodium salt of flurbiprofen and which were analyzed by the new methods (see Results section). We believe it is much more relevant to use parameter values in simulations similar to those estimated from real data than to use random numbers. For each data set 12 concentrations were generated corresponding to the times 0. 
Analysis of Real Concentration-Time Data
Mesoridazine
Data of Ganes (34) were used. Commercial tablets (Serentit | Sandoz) of 12.5, 25, and 50 mg (free base), containing the drug as mesoridazine besylate, were administered to normal human beings as single doses at 2-week intervals. Venous plasma samples were collected prior to drug administration and at 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 32, 48, and 72 hr following administration of the highest dose; the 10 and 15 hr samples were not collected following the two lowest doses. The unchanged drug was measured by a sensitive and specific HPLC method described in detail by Ganes (34) . Table III lists the times of the peak plasma concentrations (peak times) and the time of the first C, t pair used in the biexponential fits to Eq. (1). These were very difficult data sets to decide what points to use first for the biexponential fits. If a point too near the peak was used then either a difference of two exponential terms or a triexponential equation fit the data; a later point was then used as the first point and another biexponential fit was attempted; the process was repeated until a biexponential equation with two positive coefficients fitted the data set well. The appearance of a plot of the data also helped the process. The same data set with appropriate downslope starting time was then fitted to Eq. (5) in order to apply Method 3A and kl0 and ts were estimated using Eq. (5); the ~ and ~2 obtained in the biexponential fit to Eq. (1) were held constant when fitting to Eq. (5) was carried out. Values of k2~ and k~2 were then estimated with Eqs. (3) and (4) . Using this set of k~2, k21, and kl0 values the Exact Loo-Riegelman method (6) with the modification of Proost (7) was then applied to all of the C, t data of the same data set; fraction absorbed values were then obtained with Eq. (27) ; these were fitted to Eq. (31) by nonlinear least squares with the program MINSQ (30) to estimate ka and to for Method 3A.
Method 2 was applied by obtaining A UC with Eq. (6), MRT with Eqs. (13) and (16) and using MIT= 1/ka, where ka was obtained by application of Method 3A. A new k~0 was then obtained with Eq. (2) and the corresponding k~2 and k21 values obtained with Eqs. (3) and (4) again.
Method 4 was applied by substituting into Eq. (8) using the first time for the biexponential fit as the value of r, the A UC from Eq. (6), and B1, )q, and ~2 from the biexponential fit to Eq. (1).
Reconstructions were made using the model of Scheme 3, Eq. (34), and the constants estimated by Method 3A.
Flurbiprofen
Data of Gonzalez (35) was used. Twelve normal volunteers were each administered 25 ml of a 2.5 mg/ml aqueous solution of sodium flurbiprofen followed by 6 oz. of water after an overnight fast and the subjects were fasted for 4 hr postdose. Venous plasma samples were collected predose and at 0.083, 0.167, 0.25, 0.33, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24, 30, 36, and 48 hr postdose. Unchanged flurbiprofen was assayed by a specific and sensitive HPLC method with fluorescence detection described in detail by Szpunar (36) .
It was less difficult with the flurbiprofen data than with the mesoridazine data to decide which C, t pair should be the first data point for the biexponential fit to Eq. (1). For Subjects 1 and 4-12, the 2-hr point was the starting point and for Subjects 2 and 3, the 4-hr point was used. Analyses were carried out on the 12 sets of C, t data as described above for the mesoridazine data.
Reconstructions were carried out using the model of Scheme 3, Eq. (34), and the constants obtained via Method 3A.
Labetalol
Two hundred milligrams of labetalol HC1 in 40 ml of solution was administered to each of nine normal volunteers as an intestinal infusion over a 4-hr period via a small bowel intubation tube. This study was performed under contract for Schering Corporation. The venous plasma concentrations of labetalol measured in this study are listed in Table A of the Appendix. Since r=4 in this case, MIT= r/2 = 2hr and Methods 2 and 4 are most appropriate to estimate disposition parameters and were the only methods employed. Eqs. (2), (3), (4), and (13) were used for Method 2 and Eqs. (3), (4), (8), and (13) were used for Method 4. Labetalol concentrations from 4-24 hr were used for the biexponential fittings to Eq. (1).
Reconstructions were carried out using the model of Scheme 5, Eqs. (38) and (39) , and the parameters estimated by Method 2.
Flunarizine
Flunarizine pharmacokinetics were first described by Kapetanovic et al. (37) . They administered 30 mg single oral doses of flunarizine to 12 epileptic patients and drew plasma samples over a 32-day period. They fitted "postabsorptive" concentrations to a triexponential equation for each patient but did not specify which C, t data points were used. They also reported values of the disposition parameters k12, k21, k13, k31, and k~0 for the classical threecompartment model (Scheme 2) but apparently did not correct for the fact the postabsorptive oral data were fitted to the triexponential equation rather than bolus iv data as required by the equations they apparently used.
In a study carried out by J. C. Sackellares in the Department of Neurology, The University of Michigan Medical School, five epileptic patients were administered single 30 mg oral doses of flunarizine and venous plasma samples were collected for a 70-day period postdosing. The plasma samples were assayed for flunarizine by the Epilepsy Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD. The plasma concentrations are listed in Table B of the Appendix. The first downslope data point taken for the triexponential fit to Eq. (10) was 7.9, 6, 6, 6, and 12 hr for subjects M01LH, M07CL, M02SL, M03PS, and M05AL, respectively. The Cr value for each data set was obtained by substituting the time value indicated by the asterisk in Table B of the Appendix into Eq. (10) and the AUC was obtained with Eq. (6).
Method 3A was applied by fitting postabsorptive data to Eq. (11) using the ~L~s of Eq. (10) as constants and estimating kl0, Z and ts. Equations of Gibaldi and Perrier (3) were used to obtain k21, k31, k12, and k~3. The Exact Loo-Riegelman method (6) with the Proost modification (7) was then applied to all of the C, t data of the same data set and fraction absorbed values were estimated with Eq. (27) . The FA, t data were computer-fitted to Eq. (31) to estimate ka and to for Method 3A.
Method 3B was applied using Eq. (11) and estimating ts, k~o, Z, ~, ,~2, and ~13 by the method of least squares and the program MINSQ (30) .
Method 5 was applied by fitting postabsorptive C, t data to Eq. (12) with r, Z, and kl0 as estimated parameters. The remainder of the disposition rate constants were then estimated as described above for Method 3A.
The Exact Loo-Riegeman method (6) with the Proost modification (7) was then applied to all the C, t data of each data set using the disposition parameters obtained by Methods 3A and 5 then the AT/Vp data were treated as described above for Method 3A.
Reconstructions were performed using the model of Scheme 4, Eq. (35), and the constants obtained via Methods 3A and 5.
Diazepam
Data used were those given in detail by Kaplan et al. (38) . (38) reported coefficients and exponents of triexponential fits of the iv data, as well as k12, k21, k13, k3~, and k~0 of the model of Scheme 2, we refit these data and found our fits had lower sums of squared deviations than those reported (38) . The disposition parameters for Method 1 were estimated from the coefficients and exponents of the triexponential equation using the equations of Gibaldi and Perrier (3).
There were nine pairs of postabsorptive oral C, t data in the 2-to 24-hr period for each subject and each set was computer-fitted to Eq. (10) using the program RSTRIP (30) with equal weights. Disposition parameters for the model of Scheme 2 were estimated by Methods 3A and 5 by similar procedures as described above under flunarizine. Using the disposition parameters estimated by these methods the Exact Loo-Riegelman method (6) with the Proost modification (7) was applied to all of the C, t data of each data set. FA values were then obtained with Eq. (27) 
. Table IV gives results of application of Methods 3A and 5 to the errorfree data generated as described under Simulations in the Experimental section. The Exact Loo-Riegelman method (6,7) was applied to the C, t data using the disposition parameters estimated by Methods 3A and 5. The AT~ Vp data were fitted to Eq. (28) and the estimated A~/Vp and ka values are also listed in Table IV . Using Method 3A the mean error in the parameter estimates was 1.28% and the mean absolute error was 3.0%. Using Method 5 the mean error was 1.95% and the mean absolute error was 4.81%. The largest errors were in the ka estimates. The measures of fit, namely, r 2 and Model Selection Criterion (MSC) were all very high in these fittings. Table IV . These methods are explained by the captions of these two figures.
RESULTS
Simulations
Using the parameters estimated by Method 3A in Table V (42), where B3 = Bt +B2.
C = BI e-~lt + B2 e-Z2t-B3
The following fractional area was calculated:
Using the estimated parameters by Methods 3A in Table IV the fractional areas were 0.106, 0.104, and 0.099 for Sets l, 2, and 3, respectively. Table IV were used. The postabsorptive po data (A points in the figure ) from 2.5-32 hr (only the 2.5-12 hr data are shown in the figure) were computer-fitted to Eq. (9) and r=0.815 hr was estimated. This fit was based on the oral data being treated as postinfusion data. Hence, one can infer the infusion curve (O points in the figure) from 0-0.815 hr followed by postinfusion fall off (Fq) points) from 0.815 to 2.5 hr which was based on Eq. (19).
Thus, the new methods work satisfactorily with the model of Scheme 3 when the ratios ka/)`l and ka/)`2 and the fractional areas have magnitudes as given above. Additional simulations (not shown) indicated that as the ratios ka/ ).1 and ka/)`2 decreased and the fractional area increased, the accuracy of estimates of the disposition parameters kl0, k21, and k~0 decreased.
Analysis of Real Concentration-Time Data
Mesoridazine ( Biexponential Disposition) Table V 
Flurbiprofen (Biexponential Disposition)
Table VI lists the mean, CV, and range of k12, k21, and kl0 o'f the model of Scheme 1 estimated by Methods 2, 3A, 3B, 4, and 5 for flurbiprofen in 12 subjects following oral administration of a solution of sodium flurbiprofen. There were 300 parameter values estimated from the flurbiprofen data. Table VII lists results of ANOVA of the disposition parameters of flurbiprofen. The mean square for methods was not significant (F=0.08, p> 0.25); almost all the variation was associated with subjects and rate constants. The absorption and disposition parameters of flurbiprofen were remarkably similar when determined by the different methods as can be seen by comparing the mean and range of values for each parameter by the five methods (Table VI) .
In Method 3A one iterates for the parameters kl0 and ts of Eq. (5) but holds )`1 and )`z constant after the latter parameters have been obtained in the biexponential fit to Eq. (1). In Method 3B one iterates for all the parameters )`1, )`2, kl0, and ts of Eq. (5). In Method 5 one iterates for kl0 and r of Eq. (9) but hold )`1 and )`2 constant as in Method 3A. We used the coefficient of determination (r z) and the MSC as measures of fit as well as the standard deviation of the estimated parameter, s, or the corresponding coefficient of variation, s/P, where P is the estimated parameter value. One expects s and s/P to be larger for Method 3B than for Methods 3A and 5 on the basis of Table VIII.  Table IX gives results of ANOVA of the disposition rate constants of flunarizine. The mean square for methods was not significant (F= 0.00017, p > 0.25). The absorption and disposition parameters of flunarizine were very similar when determined by the two methods as can be seen by comparing the values in Table VIII. With the flunarizine data Method 3A was superior to Method 5 in the estimation of kl0 since the s/P ratio for the former averaged 0.107 (range 0.0702-0.178) compared with 0.552 (range 0.139-1.08) for the latter.
Flunarizine ( Triexponential Disposition)
The 2~1 values are also listed at the bottom of 
Labetalol (Zero-Order Input and Biexponential Disposition)
Table X lists the disposition parameters of the two-compartment open model (Scheme 1) of the individual subjects given labetalol by constant rate intestinal infusion over 4 hr. Overall mean rate constants were k~0 = 0.319 hr -1, k12=0.558 hr -1, and k21 =0.298 hr -1. Two-factor ANOVAs indicated that the mean square for methods was not significant (p > 0.10) for each rate constant when data in Table X were analyzed.
The Exact Loo-Riegelman method (6,7) was applied to the C, t data in the 0-4 hr range and A~/Vp was found to be equal to klo (AUC) in each case, hence Eq. (27) was used to estimate FA values. For each of the nine subjects the least squares FA vs. t line forced through the origin was obtained; the slopes are the input rates (ko/A~ in fraction/hr) listed in the last two columns of Table X. The theoretical rate= 1/4=0.250 hence the (Table X) and Eqs. (38) and (39) were used.
Diazepam ( Triexponential Disposition and Biexponential Absorption)
Table XI lists the disposition and absorption parameters estimated from oral C, t data of four subjects who were administered 10 mg doses of diazepam. Ar/Vp values obtained via the Exact Loo-Riegelman method (6,7) were computer-fitted to Eq. (29) and the estimates of kl, k2, and Aoo/ Vp obtained are summarized in Table XI.  Table XII gives results of ANOVA of the diazepam disposition parameters for Subjects 1-3 only since Subject 4 gave bi-rather than triexponential disposition after iv administration. Thus disposition was nonconstant for Subject 4. The mean square for methods was not significant (F=0.33, p> 0.25) indicating that disposition was constant intrasubject for Subjects 1-3. Table XIII gives results of ANOVA of the diazepam absorption parameters of the four subjects. Again the mean square for methods was not significant (F= 0.45, p > 0.25).
The overall mean rate constants for diazepam were klo=0.123 hr -1, k12= 1.77 hr -l, k13=0.384hr -1, k21=0.959 hr -1, k31=0.0629 hr -1, kl = 1.66 hr-1, and k2 = 5.05 hr-t.
In the estimation of kl0 of diazepam Methods 3A and 5 gave mean s~ P ratios of 1.29 and 1.52, respectively. In the estimation of Z, Methods 3A and 5 gave mean s/P ratios of 0.934 and 1.25, respectively. Hence, Method 3A was superior to Method 5 from this point of view, but the difference between the methods was not nearly as great as in the case of flunarizine.
In the case of the model of Scheme 6 and the five-term polyexponential Eq. (40), it is much more difficult to estimate a "fractional area" as was 
B1/2l
Fractional area 3 = (47) gl+B2_t_n3q_n4wfl5
A,l ~2 ~3 kl k2
The intravenous data gave a mean Fractional area 2 of 0.894 with a coefficient of variation of 11.2%. The oral data gave a mean Fractional area 3 of 0.891 with a coefficient of variation of 21.9%. This indicates that the intravenous and oral data were very comparable. Now 1-0.895 =0.105, a value very similar to the Fractional area 1 reported above under Simulations and also under Flurbiprofen. Figure 8 shows reconstructions of the oral diazepam data of Subject 3 using parameters estimated by the three methods. The peak concentration was underestimated in each case. The same type of underestimation occurred with data of the other three subjects. However, when all four data sets were fitted by nonlinear least squares to a five-term polyexponential equation using the program RSTRIP (30) the same type of underestimation of the peak concentration occurred in each case.
Evidence that the new methods are superior to polyexponential fitting as done classically was provided by the diazepam results. Fig. 9 supports the lack of significance of the methods mean square of Table XII. With the five-term RSTRIP fit of the oral data it was difficult to assign each of the five exponents to disposition or absorption and the lower panel of Fig. 9 is about the best results which could be obtained. Thus with triexponential fitting of postabsorptive C, t data the exponents obtained correlate much better with the exponents obtained in fitting iv data of the same subjects than do the exponents obtained in classical fitting of all C, t data to a polyexponential equation. 2. Absorption analysis can follow one or more disposition methods leading to elaboration of a complete compartment model from a single set of extravascular concentration-time data.
TIME (HOURS)
3. Existing microcomputer software available in U.S. market is satisfactory to apply the methods.
4. Once the absorption and disposition parameters have been estimated a reconstruction trend line may be drawn through the original C, t data.
5. Once the complete compartment model has been elaborated from a set of extravscular C, t data then one can infer intravenous C, t data and derive parameters of system analysis (33, (39) (40) (41) (42) (43) from extravascular data.
6. Absorption plots may be made from multicompartmental extravascular data only, providing quantitation in determining the effects of formulation factors on performance of rapid release dosage forms in animals and human beings.
7. The true normalized input rate may be estimated as evidenced by our results with labetalol.
8. If constancy of disposition is assumed one may use the new methods with C, t data from a rapid-release dosage form such as a solution to determine disposition parameters then use these with C, t data from a sustainedrelease dosage form to obtain absorption kinetics of the sustained-release dosage form. Thus, intravenous administration is avoided.
The disadvantages of the new methods are:
1. They are only applicable to linear data~ 2. They are only applicable to C, t data obtained from rapid-release dosage forms. Ratios ka/2~l and ka/A2 and fractional areas have been reported and aid in quantitating how rapid absorption must be. 3. They do not determine absolute bioavailability. 4. The methods provide the wrong compartment model if there are vanishing exponential terms (44) .
Preferred Methods
When one has no prior knowledge of input kinetics, then Method 3A is the preferred method. Method 3A produced smaller standard deviations of estimated parameters than Method 5. When input is known to be zero order and the input time, r, is known then Methods 2 and 4 are preferred as in the case of labetalol administered by intestinal infusion.
Method 3B gave much larger standard deviations of the estimated parameters than Method 3A because the number of parameters estimated with Method 3B is larger, and hence the degrees of freedom smaller, than with Method 3A. However, the parameter values estimated via Methods 3A and 3B from the same set of data were not significantly different.
Absorption Kinetics
Fifty sets of real extravascular C, t data were analyzed, each set by from two to six different methods, making a total of 198 compartment model analyses. In all cases absorption was described well by one of three models, namely, either simple first-order, two consecutive first-order processes, or a zero-order process. However, the description of absorption by a kinetic equation is not essential to the process and, conceivably, one could limit analysis of a set of C, t data to a plot of AT/Vp vs. time, which could not be described by a simple kinetic equation.
Constancy of Disposition
Data from the literature which are summarized in Tables I and II indicate that disposition is often not constant intrasubject. Our analysis of the diazepam data, where intravenous as well as oral data were available, indicate that disposition was constant intrasubject for 3 of 4 subjects. The important point is that the new methods provide a means of testing the hypothesis of constancy of disposition. The coefficient of the ith polyexponential term when postinfusion data have been fitted. k21 + k31. 
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